158205-18-6

Basic information

• Product Name: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE
• Synonyms: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE;N-(6-BroMo-1-oxo-2,3-dihydro-1H-inden-5-yl)acetaMide
• CAS NO: 158205-18-6
• Molecular Formula: C₁₁H₁₀BrNO₂
• Molecular Weight: 268.11
• Mol File: 158205-18-6.mol

Chemical Properties

• Melting Point: 162-164 °C
• Boiling Point: 458.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.631±0.06 g/cm3(Predicted)
• PKA: 13.60±0.20(Predicted)
• CAS DataBase Reference: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE(158205-18-6)
• EPA Substance Registry System: N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE(158205-18-6)

Safety Data

• Hazardous Substances Data: 158205-18-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE is utilized as a research compound for its potential as a drug candidate. Its unique chemical structure and properties make it a valuable subject for studies aimed at understanding its pharmacological profile and identifying its therapeutic potential.
Used in Drug Development:
In the field of drug development, N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE is considered for its potential applications in treating various diseases and conditions. Its exploration as a therapeutic agent is driven by the need to discover new and effective treatments, with ongoing research focused on determining its safety, efficacy, and optimal use in clinical settings.
Used in Chemical Synthesis:
N-(6-BROMO-2,3-DIHYDRO-1-OXO-1H-INDEN-5-YL)ACETAMIDE may also be employed in chemical synthesis processes, where its unique structure can be leveraged to create new compounds with potential applications in various industries, including pharmaceuticals, materials science, and more.

Upstream product

• 157701-33-2 5-acetylamino-6-bromoindane 
• 24425-40-9 indan-5-amine 
• 59856-06-3 5-acetamidoindane 

Downstream Products

• 158205-19-7 5-Amino-6-bromo-1-indanone 
• 501169-57-9 tert-butyl 4-[N-(5-acetamido-6-bromoindan-1-yl)amino]benzoate 
• 851107-84-1 N-(6-bromo-4-nitro-1-oxo-2,3-dihydro-1H-inden-5-yl)acetamide 
• 851107-86-3 4,5-diamino-indan-1-one 
• 909555-35-7 7-benzyl-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 851107-88-5 7-(4-fluoro-benzylidene)-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 851107-89-6 7-(4-fluorobenzyl)-7,8-dihydroindeno[4,5-d][1,2,3]triazol-6(3H)-one 
• 501170-72-5 5-benzyloxyacetamido-6-bromoindan-1-one 
• 501170-90-7 tert-butyl 4-{N-[2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]amino}benzoate 
• 501170-76-9 tert-butyl 4-[N-(5-(2-benzyloxy-ethanoylamino)-6-bromoindan-1-yl)amino]benzoate 
• 501132-07-6 tert-butyl 4-{N-[2-hydroxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoate 
• 501170-80-5 tert-butyl 4-[N-(5-(2-benzyloxy-ethanoylamino)-6-cyanoindan-1-yl)amino]benzoate 
• 501170-85-0 tert-butyl 4-{N-[2-benzyloxymethyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]amino}benzoate 
• 174487-71-9 4-{N-[(6R/6S)-2-Methyl-4-oxo-3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid 

Relevant articles and documents

Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity

IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent molecule 19 that achieves robust in vivo inhibition of cytokines relevant to human disease.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), and methods of use as lnterleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of Formula (0), Formula (I), and Formula (II) and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

A structure-guided approach to an orthogonal estrogen-receptor-based gene switch activated by ligands suitable for in vivo studies

A strategy to obtain a fully orthogonal estrogen-receptor-based gene switch responsive to molecules with acceptable pharmacological properties is presented. From a series of tetrahydrofluorenones active on the wild-type estrogen receptor (ER) an inactive

Antifolate chemistry: Synthesis of 4-{N-[(6RS)-2-methyl-4-oxo- 3,4,7,8-tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid via a (propargyl)Co2(CO)6+ complex

A new route to compound 3 (4-{N-[(6RS)-2-methyl-4-oxo-3,4,7,8- tetrahydro-6H-cyclopenta[g]quinazolin-6-yl]-N-(prop-2-ynyl)amino}benzoic acid), a crucial intermediate for the synthesis of potent inhibitors of thymidylate synthase (TS), is described. In this sequence the C6-N10 bond was constructed first, by the reductive amination of 5-acetamido-6-bromoindan-1-one 6 with tert-butyl 4-aminobenzoate, then the cyclopenta[g]quinazolinone ring was formed and the propargyl group was introduced on the N10-position using the (propargyl)Co2(CO)6+ complex as the electrophilic propargyl reagent.

5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2

The Compound of Formula I and pharmaceutically acceptable salts thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.

Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives

The recent discovery of an alternative form cyclooxygenase (cyclooxygenase-2, COX-2), which has been proposed to play a significant role in inflammatory conditions, may provide an opportunity to develop anti- inflammatory drugs with fewer side effects tha

Synthesis of 5-methanesulfonamido-6-(2,4-difluorophenylthio)-1-indanone

The ethylene ketal of 5-nitro-6-bromo-1-indanone 6 was prepared via oxidation of N-(6-Bromo-5-indanyl)-acetamide 1. A subsequent mild displacement and elaboration to 6-thiosubstituted-5-amino indanone derivative 10 is also described.

ALKANESULFONAMIDO-1-INDANONE DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASE

Disclosed are compounds of Formula I useful in the treatment of cyclooxygenase mediated diseases such as pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, bums, injuries